GoHealth(US:GOCO)2024-05-09 17:18Financial Performance - Q1'24 Cash Adjusted EBITDA was $70 million, compared to $78 million in Q1'23[16] - The company reported a $74 million improvement in Quarter-End Cash Adjusted EBITDA[14] - Q1'24 Adjusted Gross Margin per Submission was $216, an 7% improvement compared to $202 in Q1'23[20] - Sales per Submission increased by 8% from $794 in Q1'23 to $856 in Q1'24[20] - Cost per Submission increased by 8% from $592 in Q1'23 to $640 in Q1'24[20] Revenue and Adjusted EBITDA - Q1'24 TTM Reported Revenue was $734.4 million, a decrease from $737.1 million in Q1'23 TTM[39] - Q1'24 TTM Reported Adjusted EBITDA was $71.9 million, an increase from $73.2 million in Q1'23 TTM[39] - Q1'24 Net revenues were $185.6 million, compared to $183.158 million in Q1'23[55] - Adjusted EBITDA for Q1'24 was $26.894 million, compared to $28.778 million in Q1'23[55] Non-GAAP Measures - The company uses non-GAAP financial measures, including Adjusted EBITDA and Cash Adjusted EBITDA, to evaluate performance[37] - Cash Adjusted EBITDA equals Adjusted EBITDA plus or minus the year-over-year change in net contract assets[45]